RI
CNCE

RTW Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

RTW Investments’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,688,448
Closed -$20.4M – 58
2019
Q1 		$20.4M Buy
1,688,448
+899,571
+114% +$13.3M 1.39% 23
2018
Q4 		$9.9M Buy
+788,877
New +$10.9M 0.91% 28

Other funds holding CNCE

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

RTW Investments's CNCE Position: Q2 2019 in Review

RTW Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 1,688,448 shares — an estimated $20.4M sold.

RTW Investments first reported a position in CNCE in Q4 2018 and held it in 2 quarters. The position peaked at $20.4M in Q1 2019. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

  • RTW Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • RTW Investments sold 1,688,448 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $20.4M.
  • RTW Investments first reported a position in Concert Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
  • RTW Investments's Concert Pharmaceuticals, Inc. position peaked at $20.4M in Q1 2019.
  • 87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on RTW Investments's 13F filing for Q2 2019, filed 14 Aug 2019.